NanoViricides Files Quarterly Report
WEST HAVEN, Conn., May 23, 2011 (BUSINESS WIRE) -- NanoViricides, Inc. (the
"Company"), has filed its quarterly report with the Securities and Exchange
Commission on Friday, May 20th, in a timely fashion.
The Company reported that it had approximately $7.763M in cash and approximately
$523,000 in prepaid expenses and other cash equivalent assets as of March 31,
2010, the end of the reporting quarter. The shareholder equity stood at
approximately $9.048M. In comparison, the Company had approximately $9M in cash,
$560,000 in prepaid expenses and other cash equivalent assets, and $9.367M in
shareholder equity as of the quarter ended December 31, 2010. The Company spent
approximately $1.65M in Research and Development expenses (R&D) and approximately
$863,000 in General and Administrative expenses (G&A) in the reported quarter.
The Company's rate of cash expenditure was in line with the Company's budgeted
targets.
The Company estimates that it currently has sufficient cash in hand to achieve
the budgeted objectives through approximately 21 months of operations from
reported period. The Company has neither any long term debt, nor any short term
debt, other than small working capital accounts payables.
Subsequent to the reported period, the Company received additional financing from
a single investor, as reported previously. The Company and Seaside 88, LP, a
Florida limited partnership ("Seaside"), have entered into a new agreement to
purchase up to a total of $5M of the Company's Series B Convertible Preferred
Stock. Seaside exercised their first purchase of $2.5M of the Series B
Convertible stock on April 19, 2011. The Company has received $2.5M upon closing,
with a net of approximately $2.35M after deducting brokerage commission and
expenses. The Series B Preferred Stock is convertible into a number of shares of
the Company's common stock every two weeks. The converted shares are estimated to
represent less than five percent of the 10-day trading volume of the Company's
stock , based upon current data. The Company anticipates that the conversion of
Seaside owned Series B preferred stock will be completed by the end of September,
2011, assuming a total purchase of $5M of Series B stock by Seaside.
The Company reports that all of its drug development programs are progressing
satisfactorily.
The Company recently reported that post-infection treatment with three different
optimized FluCide(TM) drug candidates resulted in almost complete survival of
animals for the duration of the study, a greater than 95% reduction in lung
inflammation and necrosis, and a greater than 1000-fold reduction of viral load
in the lungs of animals infected with lethal dose of influenza virus. In the same
study, in contrast, animals treated with oseltamivir (Tamiflu(R), Roche) died
within 8.3 days, showed only a 50% reduction in lung inflammation and necrosis,
and demonstrated only a 2-fold reduction in lung viral load. The Company
therefore believes that it has extremely effective drug candidates against
influenza. Based on this information, the Company believes that its Flucide
program is on course for further development towards an IND submission to the
FDA.
The Company currently has five commercially important drug candidates in its
pipeline. These include FluCide(TM), HIVCide(TM), HerpiCide(TM), DengiCide(TM),
and a broad-spectrum nanoviricide eye drop formulation against viral infections
of the eye. These programs are based on the Company's platform technology that
enables specifically targeting a particular type of virus. In addition, the
Company continues its other research and development programs. These include (a)
broad-spectrum nanoviricides against a number of Neglected Tropical Diseases, and
(b) its novel ADIF(TM) ("Accurate Drug In Field"(TM)) technologies which promise
a way to attack novel viruses, whether man-made (bioterrorism) or natural (such
as SARS), before they cause a pandemic. |
